{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T22:20:55Z","timestamp":1795213255148,"version":"4.10.3"},"reference-count":38,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Several clinical and genetic factors impact overall survival (OS) in myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), including complex karyotype (CK), TP53 allelic state, and blast count. We analyzed the interplay of these factors by performing Cox regression analysis and by determining the frequency of TP53 single-hit (sh) and double-hit (dh) events and OS in MDS (n\u00a0= 747) with &amp;lt;5% blasts, with \u22655% but &amp;lt;10% blasts, and \u226510% but &amp;lt;20% blasts and AML (n\u00a0= 772). MDS with &amp;lt;5% blasts showed the best outcome, followed by with \u22655% but &amp;lt;10% blasts, and \u226510% but &amp;lt;20% blasts, and AML (median OS: 75, 54, 27, and 18\u00a0months, respectively). The same hierarchy was observed when each subgroup was divided into TP53sh, TP53dh, and without TP53 alterations (alt), revealing a dismal outcome of TP53dh in all subgroups (17, 10, 8, and 1\u00a0month[s], respectively). MDS with &amp;lt;5% blasts differed from the other subgroups by showing predominantly TP53sh (76% of TP53alt cases), and by an independent adverse impact of CK on OS (hazard ratio, 5.2; P\u00a0&amp;lt; .001). The remaining subgroups displayed many similarities, with TP53dh found at high frequencies (67%, 91%, and 71%, respectively) and only TP53alt but not CK independently influencing OS, and TP53dh showing the strongest influence. When the total cohort was split based on TP53 state, only the blast count and not CK had an independent adverse impact on OS in all subgroups. Thus, TP53dh is the strongest prognostic factor, further supporting its integration into risk stratification guidelines and classification as a separate entity. However, the blast count also influences OS independent of TP53 state, whereas CK plays a minor prognostic role.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010312","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T14:30:28Z","timestamp":1690554628000},"page":"5540-5548","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Interplay of <i>TP53<\/i> allelic state, blast count, and complex karyotype on survival of patients with AML and MDS"],"prefix":"10.1182","volume":"7","author":[{"given":"Anna","family":"Stengel","sequence":"first","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-9838","authenticated-orcid":false,"given":"Wencke","family":"Walter","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Baer","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroshan","family":"Nadarajah","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-8898","authenticated-orcid":false,"given":"Stephan","family":"Hutter","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"22","key":"2023092214150157500_bib1","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2023092214150157500_bib2","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023092214150157500_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"2023092214150157500_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023092214150157500_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2023092214150157500_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2023092214150157500_bib7","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"13","key":"2023092214150157500_bib8","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","article-title":"Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"2023092214150157500_bib9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023092214150157500_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-022-04766-2","article-title":"Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations","volume":"101","author":"Dutta","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"2023092214150157500_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","article-title":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","volume":"37","author":"Zeidan","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"2023092214150157500_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2023092214150157500_bib13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"2023092214150157500_bib14","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2023092214150157500_bib15","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1158\/1078-0432.CCR-20-2272","article-title":"Acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations - a distinct stem cell disorder","volume":"26","author":"Sill","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023092214150157500_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023092214150157500_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023092214150157500_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"33","key":"2023092214150157500_bib19","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023092214150157500_bib20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023092214150157500_bib21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023092214150157500_bib22","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53 mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"22","key":"2023092214150157500_bib23","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2023092214150157500_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2023092214150157500_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"2023092214150157500_bib26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2003.08.005","article-title":"Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group Studies","volume":"21","author":"Haferlach","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023092214150157500_bib27","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Kern","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2023092214150157500_bib28","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2023092214150157500_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.34535","article-title":"TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity","volume":"129","author":"Shallis","year":"2023","journal-title":"Cancer"},{"issue":"5","key":"2023092214150157500_bib30","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","article-title":"Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023092214150157500_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"26","key":"2023092214150157500_bib32","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023092214150157500_bib33","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023092214150157500_bib34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023092214150157500_bib35","doi-asserted-by":"crossref","first-page":"10105","DOI":"10.3390\/ijms221810105","article-title":"Personalized medicine for TP53 mutated myelodysplastic syndromes and acute myeloid leukemia","volume":"22","author":"Cluzeau","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2023092214150157500_bib36","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.3390\/ijms23147542","article-title":"New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Gallazzi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2023092214150157500_bib37","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023092214150157500_bib38","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5540\/2079955\/blooda_adv-2023-010312-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5540\/2079955\/blooda_adv-2023-010312-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:15:22Z","timestamp":1695392122000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5540\/497185\/Interplay-of-TP53-allelic-state-blast-count-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":38,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010312","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]}}}